Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Colorcon
Merck
UBS
Boehringer Ingelheim
Chubb
Johnson and Johnson
Dow
Teva

Generated: August 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Thiophene sulfonamides useful as carbonic anhydrase inhibitors
Abstract:Thiophene sulfonamides and pharmaceutical compositions containing the compounds useful in controlling intraocular pressure are disclosed. Methods for controlling intraocular pressure through administration of the compositions are also disclosed.
Inventor(s): Dean; Thomas R. (Weatherford, TX), Chen; Hwang-Hsing (Fort Worth, TX), May; Jesse A. (Fort Worth, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Filing Date:Nov 27, 1990
Application Number:07/618,765
Claims:1. A compound selected from the group consisting of:

3,4-Dihydro-2-methyl-4-(2-methyl)propylamino-4H-thieno[3,2-e]-1,2-thiazine- 6-sulfonamide-1,1-dioxide;

3,4-Dihydro-4-methoxy-2-[2-(4-morpholino)ethyl]-4H-thieno[3,2-e]-1,2-thiazi ne-6-sulfonamide-1,1-dioxide,

3,4-Dihydro-4-ethylamino-2-methyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonami de-1,1-dioxide;

3,4-Dihydro-4-ethylamino-2-allyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamid e-1,1-dioxide;

3,4-Dihydro-4-ethylamino-2-n-propyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfona mide-1,1-dioxide;

3,4-Dihydro-4-ethylamino-2-(2-methoxyethyl)-4H-thieno[3,2-e]-1,2-thiazine-6 -sulfonamide-1,1-dioxide; and

3,4-Dihydro-4-hydroxy-2-[2-(4-morpholino)ethyl]-4H-thieno[3,2-e]-1,2-thiazi ne-6-sulfonamide-1,1-dioxide.

2. The compound of claim 1 which is

3,4-Dihydro-4-ethylamino-2-methyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonami de-1,1-dioxide.

3. (+)-3,4-Dihy dro-4-ethylamino-2-methyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-d ioxide.

4. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the compound of claim 1 in a pharmaceutically acceptable carrier.

5. The formulation of claim 4 wherein the compound concentration is between about 0.1 and 10% by weight.

6. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the compound of claim 3 in a pharmaceutically acceptable carrier.

7. The formulation of claim 6 wherein the compound concentration is between about 0.1 and 10% by weight.

8. A method for controlling intraocular pressure which comprises topically administering to the affected eye a therapeutically effective amount of the compound of claim 1.

9. A method for controlling intraocular pressure which comprises topically administering to the affected eye a therapeutically effective amount of the compound of claim 3.

10. A method for controlling intraocular pressure which comprises topically administering the formulation of claim 1.

11. A formulation for controlling intraocular pressure, comprising between about 0.25 wt % and 5.0 wt % (+)-3,4-Dihydro-4-ethylamino-2-methyl-4H-thieno[3,2-e]-1,2-thiazine-6-sulf onamide-1,1-dioxide in a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Colorcon
Deloitte
QuintilesIMS
Dow
Covington
US Army
Argus Health
Queensland Health
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot